Valuation: Palvella Therapeutics, Inc.

Market Cap 2.26B 2.03B 1.85B 1.69B 3.19B 212B 3.29B 22.33B 8.9B 113B 8.48B 8.3B 358B P/E 2026 *
-24x
P/E 2027 * -17.8x
Enterprise Value 2.07B 1.86B 1.7B 1.55B 2.92B 195B 3.01B 20.45B 8.15B 104B 7.77B 7.6B 328B EV / Sales 2026 *
-
EV / Sales 2027 * 91.8x
Free-Float
88.79%
Yield 2026 *
-
Yield 2027 * -
1 day+9.83%
1 week+17.65%
Current month+17.65%
1 month+34.33%
3 months+10.98%
6 months+32.09%
Current year+64.27%
1 week 141.98
Extreme 141.98
176.94
1 month 118.22
Extreme 118.225
176.94
Current year 72.22
Extreme 72.225
176.94
1 year 72.22
Extreme 72.225
176.94
3 years 11.17
Extreme 11.17
176.94
5 years 11.17
Extreme 11.17
176.94
10 years 11.17
Extreme 11.17
176.94
Date Insider Type Main position Quantity % Market Cap. Importance
14/10/26 Sell

Chairman

-7,174 0.0498%
16/9/26 Exercice

Chief Operating Officer

12,906 0.0896%
15/9/26 Sell

Chairman

-1,777 0.0123%
Change 5-day change 1-year change 3-year change Capi.($)
+9.83%+17.65%+118.68% - 2.26B
-4.83%+2.88%+55.87%+69.12% 69.4B
+0.02%+1.07%+10.63%+76.66% 57.24B
-1.34%+2.98%+24.79%+100.18% 57.62B
+2.39%+1.68%+28.91%+37.00% 43.65B
+5.61%+10.71%+23.36%+109.03% 44.03B
+8.28%+0.47%+213.14%+792.32% 38.08B
-1.86%+11.46%+26.67%+61.40% 36.31B
-2.97%-9.84%+88.86%+76.17% 32.61B
-2.18%+5.68%+36.21%-0.69% 25.47B
Average +1.32%+2.36%+62.71%+146.80% 40.67B
Weighted average by Cap. +0.17%+2.44%+52.57%+139.06%

Financials

2026 *2027 *
Net sales - 24.63M 22.09M 20.19M 18.43M 34.72M 2.32B 35.82M 243M 97.04M 1.24B 92.45M 90.47M 3.9B
Net income -94.52M -84.78M -77.48M -70.73M -133M -8.89B -137M -934M -372M -4.74B -355M -347M -14.97B -137M -123M -112M -102M -193M -12.87B -199M -1.35B -540M -6.87B -514M -503M -21.69B
Net Debt -191M -171M -156M -143M -269M -17.92B -277M -1.88B -751M -9.56B -715M -700M -30.18B -
Projected Income Statement - Annual - Palvella Therapeutics, Inc.
Logo Palvella Therapeutics, Inc.
Palvella Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies to treat patients suffering from serious, rare genetic skin diseases for which there are no FDA-approved therapies. The Company is developing a pipeline of product candidates based on its patented QTORIN platform, with an initial focus on serious, rare genetic skin diseases, many of which are lifelong in nature. Its QTORIN product candidates are developed to accommodate the cargo at high concentrations in order to drive sufficient drug to its target deep in the epidermis and dermis. The Company's lead product candidate, QTORIN 3.9% rapamycin anhydrous gel (QTORIN rapamycin), is being evaluated in the Phase III SELVA clinical trial in microcystic lymphatic malformations and the Phase II TOIVA clinical trial in cutaneous venous malformations.
Employees
-
Date Price Change Volume
07/11/26 USD 171.95 +9.62% 319,385
05/11/26 USD 156.85 -3.35% 269,522
04/11/26 USD 162.28 +6.11% 407,143
03/11/26 USD 152.93 +4.51% 339,565
02/11/26 USD 146.33 +0.12% 303,459
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
MarketScreener Ratings - Palvella Therapeutics, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
16
Last Close Price
156.85USD
Average target price
228.40USD
Spread / Average Target
+45.62%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Palvella Therapeutics, Inc.
  1. Stock Market
  2. Stocks
  3. PVLA Stock